Reduce PVR by 47 percent! Johnson & Johnson's Opsumit and Tadalafil Phase IV clinical trials met primary endpoint
Reduce PVR by 47 percent! Johnson & Johnson's Opsumit and Tadalafil Phase IV clinical trials met primary endpoint https://whatchinareads.com/article/?uid=bd02aece3cb511ed99bcc7030b3aab5e
2022-09-25: [Article Link] The data from the OPTIMA study were released by the company Actelion under the banner of Johnson and Johnson. This is a forward-looking, multi-centre, single-arm, open-ended, IV phase experiment to assess the efficacy, safety and tolerance of newly diagnosed pulmonary arteries (PAH) patients with Opsumit
Please
sign in to continue reading and access original article links of locked articles.
Subscribe now for full access.